UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.

UBS sees approximately 250% upside potential for Viking shares over the next year, citing the possibility that Viking’s weight-loss candidates could compete with established drugs from Eli Lilly and Novo Nordisk. This is an analyst outlook, not a reported clinical or commercial outcome.